AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
Gemtuzumab ozogamicin (GO), an immunoconjugate between an anti-CD33 antibody and a calicheamicin-γ(1) derivative, induces remissions and improves survival in a subset of patients with acute myeloid leukemia (AML). As the mechanisms underlying GO and calicheamicin-γ(1) resistance are incompletely und...
Enregistré dans:
Auteurs principaux: | David B Rosen, Kimberly H Harrington, James A Cordeiro, Ling Y Leung, Santosh Putta, Norman Lacayo, George S Laszlo, Chelsea J Gudgeon, Donna E Hogge, Rachael E Hawtin, Alessandra Cesano, Roland B Walter |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/cdee93bca07145d3b4ee0e020e486f40 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
par: Hien K Duong, et autres
Publié: (2009) -
Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
par: Ayşe Hilal Eroğlu Küçükdiler, et autres
Publié: (2021) -
Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series
par: Giancarlo Fatobene, et autres
Publié: (2021) -
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
par: Sonia Jaramillo, et autres
Publié: (2021) -
Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
par: Thomas X
Publié: (2014)